Sintilimab in Cancer of Unknown Primary

Status Active, not recruiting

Clinical Trial Summary

This is a Phase 2 clinical trial evaluating the efficacy and safety of sintilimab in subjects with CUP. Up to 45 subjects with CUP will be enrolled. Subjects will be treated with sintilimab at 200 mg via intravenous (IV) administration on Cycle 1 Day 1. The treatment will repeat every 3 weeks until progressive disease (PD), intolerable toxicity, initiation of new anti-tumor therapy, withdrawal of consent, lost to follow-up, death, completion of therapy, or any other investigator-determined reasons for treatment discontinuation (whichever occurs first). Treatment will continue for a maximum period of 24 months (starting from the first dose). During the trial, tumor imaging evaluation will be initially performed once every 9 weeks (± 7 days) and will be based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. After the completion or discontinuation of the study treatment, safety follow-up and survival follow-up will be performed. Considering the rareness of the disease, the patient accrual rate is expected to be approximately 2 patients per month. The total study duration is expected to be between 24-27 months with 6-month follow up.

Clinical Trial Description

Primary Objectives: - To evaluate the safety and efficacy of sintilimab in subjects with CUP Secondary Objectives: - To evaluate the overall objective response rate (ORR) (investigator assessed), disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), overall survival (OS) and Quality of Life (QOL) on sintilimab in subjects with CUP Exploratory Objectives: - To evaluate the correlation between biomarkers in tumor tissue and efficacy, including but not restricted to PD-L1 expression level, transcriptome sequencing, single-cell sequencing, and multicolor immunohistochemistry (IHC) analyses; - To evaluate the correlation between biomarkers in peripheral blood and drug efficacy, including but not restricted to soluble PD-L1, circulating tumor DNA (ctDNA), and cytokine analyses. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05024968
Study type	Interventional
Source	M.D. Anderson Cancer Center
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	August 26, 2021
Completion date	January 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03278600` - Tissue-of-origin Directing Therapy in Patients With Cancer of Unknown Primary	Phase 3
Recruiting	`NCT04504604` - TCF-001 TRACK (Target Rare Cancer Knowledge) Study	N/A
Completed	`NCT03053466` - APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors	Phase 1
Active, not recruiting	`NCT04750109` - Carcinoma of Unknown Primary (CUP): A Comparison Across Tissue and Liquid Biomarkers
Recruiting	`NCT04952103` - Real World Study of Diagnosis and First-line Treatment Among Patients With Cancer of Unknown Primary in China
Recruiting	`NCT04969835` - A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours	Phase 1
Active, not recruiting	`NCT03498521` - A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site	Phase 2
Completed	`NCT01845337` - Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine	Phase 2
Recruiting	`NCT05263700` - FAPI-CUP- Evaluating FAPI as a Novel Radiopharmaceutical for Cancer of Unknown Primary	N/A
Active, not recruiting	`NCT03752333` - Trial of Pembrolizumab in Cancer of Unknown Primary	Phase 2
Completed	`NCT05841966` - Surgeon-performed Intraoperative Transoral Ultrasound for Cancer of Unknown Primary	N/A
Recruiting	`NCT04131621` - Nivolumab/Ipilimumab in Second Line CUP-syndrome	Phase 2
Recruiting	`NCT04459273` - Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.